226 related articles for article (PubMed ID: 35168560)
1. Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).
Sadahiro S; Sakamoto K; Tsuchiya T; Takahashi T; Ohge H; Sato T; Kondo K; Ogata Y; Baba H; Itabashi M; Ikeda M; Hamada M; Maeda K; Masuko H; Takahashi K; Sakamoto J; Kusano M; Hyodo I; Taguri M; Morita S
BMC Cancer; 2022 Feb; 22(1):170. PubMed ID: 35168560
[TBL] [Abstract][Full Text] [Related]
2. Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).
Ogata Y; Sadahiro S; Sakamoto K; Tsuchiya T; Takahashi T; Ohge H; Sato T; Kondo K; Baba H; Itabashi M; Ikeda M; Hamada M; Maeda K; Masuko H; Takahashi K; Kusano M; Hyodo I; Sakamoto J; Taguri M; Morita S
Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38833114
[TBL] [Abstract][Full Text] [Related]
3. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
[TBL] [Abstract][Full Text] [Related]
4. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
[TBL] [Abstract][Full Text] [Related]
5. S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial.
Sunami E; Kusumoto T; Ota M; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Okabe M; Tanaka C; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Takenaka N; Okude R; Sugihara K
Clin Colorectal Cancer; 2020 Mar; 19(1):22-31.e6. PubMed ID: 31917122
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502.
Sadahiro S; Tsuchiya T; Sasaki K; Kondo K; Katsumata K; Nishimura G; Kakeji Y; Baba H; Sato S; Koda K; Yamaguchi Y; Morita T; Matsuoka J; Usuki H; Hamada C; Kodaira S
Ann Oncol; 2015 Nov; 26(11):2274-80. PubMed ID: 26347106
[TBL] [Abstract][Full Text] [Related]
7. Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201).
Sadahiro S; Morita S; Sasaki K; Sakamoto K; Ohge H; Takahashi T; Tsuchiya T; Sato T; Kondo K; Ogata Y; Masuko H; Baba H; Maeda K; Hamada M; Itabashi M; Nishimura G; Takahashi K; Ikeda M; Taguri M; Kodaira S
Clin Colorectal Cancer; 2015 Dec; 14(4):277-80. PubMed ID: 26068602
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial.
Sugimoto K; Sakamoto K; Tsuchiya T; Takahashi T; Ohge H; Sato T; Taguri M; Morita S; Sadahiro S
Int J Colorectal Dis; 2023 Oct; 38(1):260. PubMed ID: 37903983
[TBL] [Abstract][Full Text] [Related]
9. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
[TBL] [Abstract][Full Text] [Related]
11. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).
Yoshida M; Ishiguro M; Ikejiri K; Mochizuki I; Nakamoto Y; Kinugasa Y; Takagane A; Endo T; Shinozaki H; Takii Y; Mochizuki H; Kotake K; Kameoka S; Takahashi K; Watanabe T; Watanabe M; Boku N; Tomita N; Nakatani E; Sugihara K;
Ann Oncol; 2014 Sep; 25(9):1743-1749. PubMed ID: 24942277
[TBL] [Abstract][Full Text] [Related]
12. Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan.
Yu YL; Tseng WK; Liao CK; Yeh CY; Chen HH; Liu YH; Liaw YW; Fan CW
BMC Cancer; 2023 Sep; 23(1):900. PubMed ID: 37749535
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
Hong KD; Lee SI; Moon HY
Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
[TBL] [Abstract][Full Text] [Related]
14. S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial.
Watanabe J; Sasaki S; Kusumoto T; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Yokota M; Tanaka C; Yamauchi J; Uetake H; Itabashi M; Takahashi K; Baba H; Kotake K; Boku N; Aiba K; Morita S; Takenaka N; Sugihara K
ESMO Open; 2021 Apr; 6(2):100077. PubMed ID: 33714860
[TBL] [Abstract][Full Text] [Related]
15. Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur-Uracil Plus Leucovorin Versus Capecitabine.
Tashiro J; Yamaguchi S; Ishii T; Kondo H; Hara K; Shimizu H; Takemoto K; Suzuki A
Clin Colorectal Cancer; 2017 Sep; 16(3):e141-e145. PubMed ID: 28216247
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival results of surgery alone versus surgery plus UFT (Uracil and Tegafur)-based adjuvant therapy in patients with stage II colon cancer.
Lin BR; Lai HS; Chang TC; Lee PH; Chang KJ; Liang JT
J Gastrointest Surg; 2011 Dec; 15(12):2239-45. PubMed ID: 21993974
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
Hasegawa K; Saiura A; Takayama T; Miyagawa S; Yamamoto J; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Oba M; Takahashi M; Mizunuma N; Matsuyama Y; Watanabe T; Makuuchi M; Kokudo N
PLoS One; 2016; 11(9):e0162400. PubMed ID: 27588959
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
[TBL] [Abstract][Full Text] [Related]
19. Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Tashiro J; Yamaguchi S; Ishii T; Suzuki A; Kondo H; Morita Y; Hara K; Koyama I
World J Surg Oncol; 2014 May; 12():145. PubMed ID: 24884880
[TBL] [Abstract][Full Text] [Related]
20. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K
Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
